Pasithea Therapeutics Warrants
KTTAW
6 hedge funds and large institutions have $8.68K invested in Pasithea Therapeutics Warrants in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
4.56% less ownership
Funds ownership: 7.98% → 3.42% (-4.6%)
71% less capital invested
Capital invested by funds: $29.9K → $8.68K (-$21.2K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$13.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KC
1
Kepos Capital
New York
| $4K | – | – | – |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $3.59K | – | – | – |
|
|
AC
3
Armistice Capital
New York
| $615 | -$13.1K | -950,000 | -95% |
|
|
MG
4
Marex Group
London,
| $308 | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $162 | +$1 | +100 | +0.8% |
|
KTTAW Hedge Fund Activity: Q1 2024 in Review
6 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q1 2024, worth a combined $8.68K — down 71% from $29.9K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new KTTAW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $1. The largest seller was Armistice Capital, cutting an estimated $13.1K.
- 6 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q1 2024, up from 5 in Q4 2023.
- Funds reported $8.68K of Pasithea Therapeutics Warrants stock for Q1 2024, down 71% quarter-over-quarter.
- 1 fund opened new Pasithea Therapeutics Warrants positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Pasithea Therapeutics Warrants buyer in Q1 2024 was Citadel Advisors, an estimated $1 added.
- The largest Pasithea Therapeutics Warrants seller in Q1 2024 was Armistice Capital, an estimated $13.1K sold.
Based on aggregated 13F filings for Q1 2024.